144 related articles for article (PubMed ID: 38652499)
1. Effectiveness and optimization of low-sodium oxybate in participants with narcolepsy switching from a high-sodium oxybate: data from the SEGUE study.
Macfadden W; Leary EB; Fuller DS; Kirby MT; Roy A
J Clin Sleep Med; 2024 Apr; ():. PubMed ID: 38652499
[TBL] [Abstract][Full Text] [Related]
2. Changes in Cataplexy Frequency in a Clinical Trial of Lower-Sodium Oxybate with Taper and Discontinuation of Other Anticataplectic Medications.
Dauvilliers Y; Šonka K; Bogan RK; Partinen M; Del Rio Villegas R; Foldvary-Schaefer N; Skowronski R; Chen A; Black J; Skobieranda F; Thorpy MJ
CNS Drugs; 2022 Jun; 36(6):633-647. PubMed ID: 35635687
[TBL] [Abstract][Full Text] [Related]
3. Development of a lower-sodium oxybate formulation for the treatment of patients with narcolepsy and idiopathic hypersomnia.
Junnarkar G; Allphin C; Profant J; Steininger TL; Chen C; Zomorodi K; Skowronski R; Black J
Expert Opin Drug Discov; 2022 Feb; 17(2):109-119. PubMed ID: 34818123
[TBL] [Abstract][Full Text] [Related]
4. Long-Term Treatment of Narcolepsy and Idiopathic Hypersomnia with Low-Sodium Oxybate.
Schneider LD; Morse AM; Strunc MJ; Lee-Iannotti JK; Bogan RK
Nat Sci Sleep; 2023; 15():663-675. PubMed ID: 37621721
[TBL] [Abstract][Full Text] [Related]
5. Long-Term Safety and Tolerability During a Clinical Trial and Open-Label Extension of Low-Sodium Oxybate in Participants with Narcolepsy with Cataplexy.
Bogan RK; Foldvary-Schaefer N; Skowronski R; Chen A; Thorpy MJ
CNS Drugs; 2023 Apr; 37(4):323-335. PubMed ID: 36947322
[TBL] [Abstract][Full Text] [Related]
6. Dosing and transition characteristics in people with narcolepsy transitioning from sodium oxybate to low-sodium oxybate: Data from the real-world TENOR study.
Husain AM; Zee PC; Leary EB; Fuller DS; Macfadden W; Candler S; Whalen M; Bae CJ
Sleep Med; 2024 Jan; 113():328-337. PubMed ID: 38103464
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of calcium, magnesium, potassium, and sodium oxybates (lower-sodium oxybate [LXB]; JZP-258) in a placebo-controlled, double-blind, randomized withdrawal study in adults with narcolepsy with cataplexy.
Bogan RK; Thorpy MJ; Dauvilliers Y; Partinen M; Del Rio Villegas R; Foldvary-Schaefer N; Skowronski R; Tang L; Skobieranda F; Šonka K
Sleep; 2021 Mar; 44(3):. PubMed ID: 33184650
[TBL] [Abstract][Full Text] [Related]
8. Calcium, Magnesium, Potassium, and Sodium Oxybates Oral Solution: A Lower-Sodium Alternative for Cataplexy or Excessive Daytime Sleepiness Associated with Narcolepsy.
Dauvilliers Y; Bogan RK; Šonka K; Partinen M; Foldvary-Schaefer N; Thorpy MJ
Nat Sci Sleep; 2022; 14():531-546. PubMed ID: 35378745
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and tolerability in people with narcolepsy transitioning from sodium oxybate to low-sodium oxybate: Data from the real-world TENOR study.
Bae CJ; Zee PC; Leary EB; Fuller DS; Macfadden W; Candler S; Steininger TL; Husain AM
Sleep Med; 2023 Sep; 109():65-74. PubMed ID: 37421868
[TBL] [Abstract][Full Text] [Related]
10. Calcium, magnesium, potassium, and sodium oxybates oral solution for cataplexy or excessive daytime sleepiness associated with narcolepsy.
Abad VC
Expert Opin Pharmacother; 2023 Jun; 24(8):875-885. PubMed ID: 37060579
[TBL] [Abstract][Full Text] [Related]
11. Implications of Oxybate Dosing Regimen for Sleep, Sleep Architecture, and Disrupted Nighttime Sleep in Patients with Narcolepsy: A Commentary.
Rosenberg R; Braceras R; Macfadden W; Candler S; Black J; Ruoff C
Neurol Ther; 2023 Dec; 12(6):1805-1820. PubMed ID: 37755650
[TBL] [Abstract][Full Text] [Related]
12. Calcium, Magnesium, Potassium and Sodium Oxybates (Xywav
Heo YA
CNS Drugs; 2022 May; 36(5):541-549. PubMed ID: 35357671
[TBL] [Abstract][Full Text] [Related]
13. Long-term safety and maintenance of efficacy of sodium oxybate in the treatment of narcolepsy with cataplexy in pediatric patients.
Lecendreux M; Plazzi G; Dauvilliers Y; Rosen CL; Ruoff C; Black J; Parvataneni R; Guinta D; Wang YG; Mignot E
J Clin Sleep Med; 2022 Sep; 18(9):2217-2227. PubMed ID: 35689598
[TBL] [Abstract][Full Text] [Related]
14. Dosing Optimization of Low-Sodium Oxybate in Narcolepsy and Idiopathic Hypersomnia in Adults: Consensus Recommendations.
Morse AM; Bogan RK; Roy A; Thorpy MJ
Neurol Ther; 2024 Jun; 13(3):785-807. PubMed ID: 38662324
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics, bioavailability, and bioequivalence of lower-sodium oxybate in healthy participants in two open-label, randomized, crossover studies.
Chen C; Jenkins J; Zomorodi K; Skowronski R
Clin Transl Sci; 2021 Nov; 14(6):2278-2287. PubMed ID: 34121333
[TBL] [Abstract][Full Text] [Related]
16. Once-nightly sodium oxybate (FT218) demonstrated improvement of symptoms in a phase 3 randomized clinical trial in patients with narcolepsy.
Kushida CA; Shapiro CM; Roth T; Thorpy MJ; Corser BC; Ajayi AO; Rosenberg R; Roy A; Seiden D; Dubow J; Dauvilliers Y
Sleep; 2022 Jun; 45(6):. PubMed ID: 34358324
[TBL] [Abstract][Full Text] [Related]
17. Effect of sodium oxybate on body mass index in pediatric patients with narcolepsy.
Dauvilliers Y; Lammers GJ; Lecendreux M; Maski K; Kansagra S; Black J; Parvataneni R; Chen A; Wang YG; Plazzi G
J Clin Sleep Med; 2024 Mar; 20(3):445-454. PubMed ID: 37942930
[TBL] [Abstract][Full Text] [Related]
18. Once-nightly sodium oxybate (FT218) improved symptoms of disrupted nighttime sleep in people with narcolepsy: a plain language summary.
Roth T; Thorpy MJ; Kushida CA; Horsnell M; Gudeman J
J Comp Eff Res; 2023 Dec; 12(12):e230133. PubMed ID: 37971303
[TBL] [Abstract][Full Text] [Related]
19. Validation of the Epworth Sleepiness Scale for Children and Adolescents (ESS-CHAD) questionnaire in pediatric patients with narcolepsy with cataplexy aged 7-16 years.
Wang YG; Menno D; Chen A; Steininger TL; Morris S; Black J; Profant J; Johns MW
Sleep Med; 2022 Jan; 89():78-84. PubMed ID: 34920345
[TBL] [Abstract][Full Text] [Related]
20. Clinician Preferences for Oxybate Treatment for Narcolepsy: Survey and Discrete Choice Experiment.
Morse AM; Krahn L; Flygare J; Kushida C; Thorpy MJ; Athavale A; Gudeman J
Adv Ther; 2023 Jul; 40(7):3199-3216. PubMed ID: 37243863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
